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raser et al. (1) reported that “high-
dose benfotiamine (300 mg/day)
supplementation over 24 months
has no significant effects upon peripheral
nerve function or soluble markers of in-
flammation in patients with type 1 diabe-
tes.” Although this conclusion may be
correct based on these findings, the clin-
ical relevance remains obscure in view of
the questionable study design. According
to the recent consensus statement of the
Toronto Diabetic Neuropathy Expert
Group (2), a possible diabetic sensorimo-
tor polyneuropathy (DSPN) can be diag-
nosed if symptoms or signs of DSPN are
present. In the case of probable DSPN, a
combination of symptoms and signs of
neuropathy is present. The authors state
that among the patients included, 56%
had subclinical neuropathy based on ab-
normal nerve conduction studies (NCS),
and 16% had probable DSPN. Unfortu-
nately, how abnormal NCS was defined
is unclear. In fact, this high percentage
is surprising given that mean sural sen-
sory nerve conduction velocity (NCV),
which is one of the most sensitive indica-
tors of DSPN, was well within the normal
range. Moreover, clinical neuropathy
scores have been used to assume prob-
able DSPN, but obviously the latter has
not been confirmed by abnormal NCS.
Because the number of subjects included
with confirmed DSPN was presumably
very low, this trial does not provide
any information on the important ques-
tion as to whether treatment with benfoti-
amine may improve DSPN or slow its
progression. The authors note that in pre-
vious studies using benfotiamine, no effect
on NCV was shown. In the study by
Stracke et al. (3) cited by the authors, im-
provement in peroneal motor NCV in
diabetic patients with DSPN was docu-
mented.
Further drawbacks of this trial are the
lack of an intention-to-treat analysis to
confirm the per protocol data and of an a
priori–specified clinically meaningful dif-
ference in peroneal motor NCV between
the two groups studied.
Recently, it has been suggested that
the progression of DSPN in the placebo
group within the setting of a randomized
clinical trial over 4-year period was slow.
Thus, for demonstration of efficacy, trials
using drugs for treatment of DSPN must
achieve a clinically relevant neurological
improvement (4). Unfortunately, the
study conducted by Fraser et al. (1) in
patients with almost normal nerve func-
tion does not leave any room for a mean-
ingful degree of improvement.
The title reads “Benfotiamine Supple-
mentation,” but the dose applied (300
mg/day) was much higher than the rec-
ommended daily adult allowance for thi-
amine (1.4 mg/day). Hence, this was
pharmacotherapy rather than vitamin
supplementation.
Finally, as far as it can be judged from
the article, the patients examined had no
chronic inflammation. Therefore, it was
foreseeable that no effect on inflammatory
markers was shown. In conclusion, it is
not surprising that 2-year treatment with
benfotiamine versus placebo did not re-
sult in meaningful differences between
the groups in nerve function or markers
of inflammation in patients without
evidence of neuropathy nor inflamma-
tion. Only trials using appropriate study
designs and end points can assess the
effects of benfotiamine on nerve dysfunc-




From the 1Institute for Clinical Diabetology,
German Diabetes Center at Heinrich Heine Uni-
versity, Leibniz Center for Diabetes Research,
Düsseldorf, Germany; the 2Department of Met-
abolic Diseases, University Hospital, Düsseldorf,
Germany; the 3Diabetes Research Unit, Sheffield
Teaching Hospitals, Sheffield, U.K.; and the 41st
Department of Medicine, Semmelweis University,
Budapest, Hungary.
Corresponding author: Dan Ziegler, dan.ziegler@
ddz.uni-duesseldorf.de.
DOI: 10.2337/dc12-0817
© 2012 by the American Diabetes Association.
Readers may use this article as long as the work is
properly cited, the use is educational and not for
profit, and the work is not altered. See http://
creativecommons.org/licenses/by-nc-nd/3.0/ for
details.
Acknowledgments—D.Z. and P.K. have re-
ceived honoraria from Wörwag Pharma for
speaking. D.Z., P.K., and S.T. have received
honoraria from Wörwag Pharma for consul-
ting activities. No other potential conflicts of
interest relevant to this article were reported.
c c c c c c c c c c c c c c c c c c c c c c c c
References
1. Fraser DA, Diep LM, Hovden IA, et al. The
effects of long-term oral benfotiamine
supplementation on peripheral nerve
function and inflammatory markers in
patients with type 1 diabetes: a 24-month,
double-blind, randomized, placebo-
controlled trial. Diabetes Care 2012;35:
1095–1097
2. Tesfaye S, Boulton AJM, Dyck PJ, et al.;
Toronto Diabetic Neuropathy Expert
Group. Diabetic neuropathies: update on
definitions, diagnostic criteria, estimation
of severity, and treatments. Diabetes Care
2010;33:2285–2293
3. Stracke H, Lindemann A, Federlin K.
A benfotiamine-vitamin B combination in
treatment of diabetic polyneuropathy. Exp
Clin Endocrinol Diabetes 1996;104:311–
316
4. Ziegler D, Low PA, LitchyWJ, et al. Efficacy
and safety of antioxidant treatment with
a-lipoic acid over 4 years in diabetic poly-
neuropathy: the NATHAN 1 trial. Diabetes
Care 2011;34:2054–2060
care.diabetesjournals.org DIABETES CARE, VOLUME 35, NOVEMBER 2012 e79
O N L I N E L E T T E R S
